These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 24506143)

  • 21. Administration of platelet concentrates suspended in bicarbonated Ringer's solution in children who had platelet transfusion reactions.
    Kobayashi J; Yanagisawa R; Ono T; Tatsuzawa Y; Tokutake Y; Kubota N; Hidaka E; Sakashita K; Kojima S; Shimodaira S; Nakamura T
    Vox Sang; 2018 Feb; 113(2):128-135. PubMed ID: 29067694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Automated preparation of platelet concentrates from pooled buffy coats: in vitro studies and experiences with the OrbiSac system.
    Larsson S; Sandgren P; Sjödin A; Vesterinen M; Gulliksson H
    Transfusion; 2005 May; 45(5):743-51. PubMed ID: 15847664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo PLT increments after transfusions of WBC-reduced PLT concentrates stored for up to 7 days.
    Dijkstra-Tiekstra MJ; Pietersz RN; Hendriks EC; Reesink HW; Huijgens PC
    Transfusion; 2004 Mar; 44(3):330-6. PubMed ID: 14996188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reactions and platelet increments after transfusion of platelet concentrates in plasma or an additive solution: a prospective, randomized study.
    de Wildt-Eggen J; Nauta S; Schrijver JG; van Marwijk Kooy M; Bins M; van Prooijen HC
    Transfusion; 2000 Apr; 40(4):398-403. PubMed ID: 10773049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Implementation of buffy coat platelet component production: comparison to platelet-rich plasma platelet production.
    Levin E; Culibrk B; Gyöngyössy-Issa MI; Weiss S; Scammell K; LeFresne W; Jenkins C; Devine DV
    Transfusion; 2008 Nov; 48(11):2331-7. PubMed ID: 18631169
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pooled platelet product using the Acrodose plus system: evaluation of feasibility, safety and efficacy.
    Sawant RB; Marathe AN
    Transfus Apher Sci; 2013 Dec; 49(3):535-8. PubMed ID: 24080148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The quality of platelet concentrates related to corrected count increment: linking in vitro to in vivo.
    Saris A; Kreuger AL; Ten Brinke A; Kerkhoffs JLH; Middelburg RA; Zwaginga JJ; van der Meer PF
    Transfusion; 2019 Feb; 59(2):697-706. PubMed ID: 30226275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preparation, storage and quality control of platelet concentrates.
    Tynngård N
    Transfus Apher Sci; 2009 Oct; 41(2):97-104. PubMed ID: 19699153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of transfusion efficacy of amotosalen-based pathogen-reduced platelet components and gamma-irradiated platelet components.
    Sigle JP; Infanti L; Studt JD; Martinez M; Stern M; Gratwohl A; Passweg J; Tichelli A; Buser AS
    Transfusion; 2013 Aug; 53(8):1788-97. PubMed ID: 23176347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized study of buffy coat platelets in platelet additive solution stored 1-5 versus 6-7 days prior to prophylactic transfusion of allogeneic haematopoietic progenitor cell transplant recipients.
    Diedrich B; Ringdén O; Watz E; Shanwell A
    Vox Sang; 2009 Oct; 97(3):254-9. PubMed ID: 19508669
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of platelet concentrate storage time reduction in patients after blood stem cell transplantation.
    Heuft HG; Goudeva L; Krauter J; Peest D; Buchholz S; Tiede A
    Vox Sang; 2013 Jul; 105(1):18-27. PubMed ID: 23521355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use.
    Osselaer JC; Doyen C; Defoin L; Debry C; Goffaux M; Messe N; Van Hooydonk M; Bosly A; Lin JS; Lin L; Corash L
    Transfusion; 2009 Jul; 49(7):1412-22. PubMed ID: 19389022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Replaced platelet concentrates containing a new additive solution, M-sol: safety and efficacy for pediatric patients.
    Yanagisawa R; Shimodaira S; Kojima S; Nakasone N; Ishikawa S; Momose K; Honda T; Yoshikawa K; Saito S; Tanaka M; Nakazawa Y; Sakashita K; Shiohara M; Akino M; Hirayama J; Azuma H; Koike K
    Transfusion; 2013 Sep; 53(9):2053-60. PubMed ID: 23252617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Buffy-coat platelet variables and metabolism during storage in additive solutions or plasma.
    Zhang JG; Carter CJ; Culibrk B; Devine DV; Levin E; Scammell K; Weiss S; Gyongyossy-Issa MI
    Transfusion; 2008 May; 48(5):847-56. PubMed ID: 18298601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion.
    Lozano M; Knutson F; Tardivel R; Cid J; Maymó RM; Löf H; Roddie H; Pelly J; Docherty A; Sherman C; Lin L; Propst M; Corash L; Prowse C
    Br J Haematol; 2011 May; 153(3):393-401. PubMed ID: 21418180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transfusion of platelet concentrates from pooled buffy-coats: comparison of bedside vs. prestorage leukofiltration.
    Müller-Steinhardt M; Schlenke P; Wagner T; Klüter H
    Transfus Med; 2000 Mar; 10(1):59-65. PubMed ID: 10760204
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reevaluation of the resting time period when preparing whole blood-derived platelet concentrates with the platelet-rich plasma method.
    Moroff G; Kline L; Dabay M; Hunter S; Johnson A; McNeil D; Nixon J; Sawyer S; Taylor H; Whitley P; Wahab F; Murphy S
    Transfusion; 2006 Apr; 46(4):572-7. PubMed ID: 16584433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of platelet activation and cytokine release during storage of platelet concentrates processed from buffy coats either manually or by the automated OrbiSac system.
    Vetlesen A; Mirlashari MR; Ezligini F; Kjeldsen-Kragh J
    Transfusion; 2007 Jan; 47(1):126-32. PubMed ID: 17207241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro function of buffy coat-derived platelet concentrates stored for 9 days in CompoSol, PASII or 100% plasma in three different storage bags.
    Cardigan R; Sutherland J; Garwood M; Bashir S; Turner C; Smith K; Hancock V; Wiltshire M; Pergande C; Williamson LM
    Vox Sang; 2008 Feb; 94(2):103-12. PubMed ID: 18034786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A system for the supply of platelets suspended in a storage medium including buffy-coat-derived platelet concentrates in combination with "split" apheresis platelets.
    Gulliksson H; Larsson S; Shanwell A; Pedajas I; Joie M; Flament J
    Transfus Sci; 1997 Mar; 18(1):33-40. PubMed ID: 10174289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.